Bernstein raised the firm’s price target on Regeneron (REGN) to $781 from $753 and keeps an Outperform rating on the shares. The firm adds myasthenia gravis to its model following the positive Phase 3 readout, increasing EPS by 7% in the out-years. Efficacy data looks competitive with approved agents, while the real differentiator is a longer dosing interval with sustained treatment effect.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron announces Phase 3 NIMBLE trial met primary, key secondary endpoints
- Regeneron’s Promising Phase 2 NSCLC Trial: A Potential Game-Changer?
- Regeneron’s Innovative Gene Therapy Study for Hemophilia B: Market Implications and Progress
- Regeneron’s Promising Phase 3 Trial for Lymphoma Treatment: What Investors Need to Know
- Regeneron’s Real-World Study on Aflibercept: Market Implications and Investor Insights